John Milad is CEO of Quanta Dialysis Technologies, where he was both a founding board member and an original investor through NBGI Ventures. John’s career spans more than twenty years, with extensive international experience in building and growing successful healthcare companies as an executive manager, board member, private equity investor and corporate financier.
Prior to his role as CEO of Quanta, John was Investment Director at NBGI Ventures, where he was closely involved with a range of innovative medical technology companies in Europe and the US, both as a board member and an investor. Previously, John has also held senior positions at Nitec Pharma AG (now Horizon Pharma plc), Atlas Venture and Nomura international. He has also served on the Board of Directors at Cellnovo Ltd, Symetis SA, BoneSupport AB and Advanced Cardiac Therapeutics Inc. He holds a BA in Political Science from The University of Chicago.